Biomica Completes Phase 1 Clinical Study of BMC128 and Nivolumab Combination Therapy

Biomica, a subsidiary of Evogene, has completed its Phase 1 clinical study evaluating the safety and tolerability of BMC128, a live bacterial product, when administered in combination with the immunotherapy drug nivolumab. The study focused on patients with advanced solid tumors, assessing the potential for the combination therapy to improve treatment outcomes.

Researchers conducted the trial to determine whether BMC128 could be safely integrated into existing cancer treatment protocols. The study monitored participants for adverse reactions and evaluated the biological activity of the bacterial product alongside nivolumab, a standard checkpoint inhibitor. Biomica officials reported that the trial met its primary objectives regarding safety and clinical data collection. The company now plans to analyze the gathered information to determine the next steps for the development of the therapeutic candidate.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI